Bakkers, C. http://orcid.org/0000-0002-9458-091X
Rovers, K. P.
Rijken, A.
Simkens, G. A. A. M.
Bonhof, C. S.
Nienhuijs, S. W.
Burger, J. W. A.
Creemers, G. J. M.
Brandt-Kerkhof, A. R. M.
Tuynman, J. B.
Aalbers, A. G. J.
Wiezer, M. J.
de Reuver, P. R.
van Grevenstein, W. M. U.
Hemmer, P. H. J.
Punt, C. J. A.
Tanis, P. J.
Mols, F.
de Hingh, I. H. J. T.
,
Thijs, A. M. J.
Lurvink, R. J.
Madsen, E. V. E.
van Meerten, E.
Kusters, M.
Versteeg, K. S.
Kok, N. F. M.
Buffart, T. E.
Boerma, D.
Los, M.
de Wilt, J. H. W.
Verheul, H. M. W.
Kruijff, S.
de Groot, D. J. A.
Koopman, M.
Funding for this research was provided by:
F. Hoffmann-La Roche (ML39718)
KWF Kankerbestrijding (10795)
Article History
Received: 14 December 2021
Accepted: 2 January 2023
First Online: 8 February 2023
Disclosures
: Prof. I.H.J.T. de Hingh received grants (paid to institute) from QP&S/RanD Biotech for research unrelated to the submitted work. Prof. Dr. P.J. Tanis received an unrestricted research grant from Allergan (LifeCell) unrelated to the submitted work. Prof. C.J.A. Punt has an advisory role for Nordic Pharma. All remaining authors have declared no conflicts of interest.